Gossamer Bio vs Roivant Sciences
GOSS and ROIV side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How GOSS and ROIV compare
Roivant Sciences is the larger company, worth 426 times as much as Gossamer Bio ($28.6B against $67.1M).
Roivant Sciences grew revenue faster over the last twelve months (102% versus 78.0% for Gossamer Bio).
Gossamer Bio keeps more of each dollar of sales as profit, with a net margin of −159% compared with −838% at Roivant Sciences.
Roivant Sciences scores higher on the StockData Score (8 against 2 for Gossamer Bio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | GOSS | ROIV |
|---|---|---|
| Size and price | ||
| Market cap | $67.1M | $28.6B |
| Share price | $10.97 | $39.53 |
| Change, 1 year | −94.9% | 85.4% |
| Change, 5 years | −98.8% | 394% |
| Beta (5Y) | 1.58 | 0.85 |
| Employees | 161 | 721 |
| StockData Score | ||
| Total score | 2 | 8 (better) |
| Valuation score | 1 (better) | 0 |
| Growth score | 1 | 1 |
| Performance score | 0 | 1 (better) |
| Health score | 0 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.9× (better) | 695× |
| P/B | – | 7.1× |
| FCF yield | −233% | −0.12% (better) |
| Growth | ||
| Revenue growth (TTM) | 78.0% | 102% (better) |
| Revenue growth, 5Y average | – | −19.1% |
| Profitability | ||
| Operating margin | −140% (better) | −1358% |
| Net margin | −159% (better) | −838% |
| FCF margin | −199% | −81.2% (better) |
| Return on equity | – | −8.2% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −10.3× | – |
| Current ratio | 0.60 | 15.56 (better) |
| Altman Z-score | −37.94 | 45.37 (better) |
| Piotroski F-score | 1 | 2 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 78.0% | 78.1% |
| Held by insiders | – | 13.9% |
| Insider net buying, 12 months | – | −$798M |
| Superinvestors holding | 1 | 1 |
| Short interest, % of float | – | 7.3% |
Go deeper
- GOSS stock overview
- GOSS income statement
- GOSS valuation and score
- ROIV stock overview
- ROIV income statement
- ROIV valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.